Arcus Biosciences Inc

RCUS

$19.53

Closing

▼-0.71%

1D

▲2.25%

YTD

Market cap

$1.49B

52 week high

$25.40

52 week low

$12.95

Volume

360,975

Check if the stock is halal

Unlock Industry-grade Shariah Compliance for global stocks. See results from 5 major Shariah standards: AAOIFI, S&P, DJIM, FTSE and MSCI.

We provide unparalleled value and service.
Screened by AAOIFI Certified Shariah Advisor & Auditor.

Get started from just $3.99/month

Market cap

$1.49B

Analysts' Rating

BUY

Price Target (Mean)

42.16667

Total Analysts

11

P/E

Operating Margin

-250.00%

Beta

0.82

Revenue Growth (Annual)

-70.75%

52 week high

$25.40

52 week low

$12.95

Div. Yield

%

EPS Annual Growth

-9.62

Note on Purification and Zakat

  • Purification and Zakat (for long-term investing) calculations are in USD per share and based on AAOIFI methodology. AAOIFI requires purification every financial period (e.g. quarterly). 
  • If you follow S&P Shariah’s Dividend-only purification, then remove the impure income % from the dividends you receive. No purification required for non-dividend paying stocks, according to S&P Shariah.
  • For Zakat, if you did not invest in a company from a long term perspective, then consider the shares as trading goods and give 2.5% of the total value if a year has passed on them. 

Company Profile

Arcus Biosciences, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing differentiated molecules and combination therapies for people with cancer. The Company involves in a portfolio of investigational products, which are in clinical development with its advanced molecule, an anti-TIGIT antibody targeting lung and gastrointestinal cancers. The Company has approximately five clinical programs that are focused on targets, including TIGIT, PD-1, HIF-2a, adenosine A2a and A2b receptors and CD73. It is evaluating three antibodies and three small molecules across 13 different clinical studies, including four Phase III studies. It is developing two investigational anti-TIGIT monoclonal antibodies, which include domvanalimab (Fc-silent) and AB308 (Fc-enabled). HIF-2a is a master transcriptional regulator of multiple genes involved in tumor progression. The Company’s investigational products also include etrumadenant and quemliclustat.